Levodopa unresponsive symptoms in Parkinson disease

Area of Science:

• Neurology
• Pharmacology

Background:

• Levodopa has been the primary symptomatic treatment for Parkinson Disease (PD) for four decades.
• It improves daily living, quality of life, and survival rates in PD patients.

Purpose of the Study:

• To review and highlight Parkinson Disease symptoms that are unresponsive to Levodopa therapy.
• To discuss the limitations of Levodopa in managing the full spectrum of PD symptoms.

Main Methods:

• Literature review of studies on Levodopa efficacy and limitations in Parkinson Disease.
• Analysis of reported cases of Levodopa-associated complications and unresponsive symptoms.

Main Results:

• Long-term Levodopa use is linked to motor fluctuations and dyskinesia.
• Levodopa shows limited efficacy for gait/balance issues and non-motor symptoms like autonomic dysfunction, pain, sleep disorders, mood disturbances, and dementia.
• Dopaminergic agents, including Levodopa, can trigger impulse control disorders.

Conclusions:

• Despite its benefits, Levodopa does not address all Parkinson Disease symptoms.
• Understanding Levodopa-unresponsive symptoms is crucial for comprehensive PD management.
• Further research is needed to address the multifaceted nature of Parkinson Disease beyond dopaminergic therapy.